Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab

Jon Arnason, Won Seog Kim, David Tucker et al. Nov 03, 2025 pp. 5309-5309 10.1182/blood-2025-5309

Abstract Introduction Odronextamab, a CD20×CD3 bispecific antibody, showed compelling efficacy and generally manageable safety in patients (...

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Karamjeet Sandhu, Marissa Del Real, Alan Macias et al. Nov 03, 2025 pp. 3352-3352 10.1182/blood-2025-3352

Abstract Blinatumomab (blina), a bispecific anti-CD19/CD3 T cell engaging antibody (Ab), provides improved outcomes in patients (pts) with r...

First miniaturized electrophoresis diagnostic platform in USA for hemoglobinopathies : From diagnosis to therapeutic monitoring in real time.

Akshat Jain, Priyaleela Thota, Umut Gurkan Nov 03, 2025 pp. 2958-2958 10.1182/blood-2025-2958

Abstract Hemoglobinopathies, including sickle cell disease (SCD) and thalassemia's, are the most common monogenic diseases globally, affecti...

Loss of the Y chromosome drives context-dependent transcriptional reprogramming in myeloid progenitors and AML1-ETO acute myeloid leukemia (AML)

Hayden Bell, Christopher Booth, Andrew Lane Nov 03, 2025 pp. 1449-1449 10.1182/blood-2025-1449

Abstract Mosaic loss of chromosome Y (LOY) is a highly prevalent somatic event in many cancers (~30% of male tumors) and is frequently obser...

Preclinical feasibility analysis for Phase I study using adoptive iNKT cell transfer to prevent GVHD

Kelsey Busken, Emily Landy, Melissa Mavers Nov 03, 2025 pp. 5967-5967 10.1182/blood-2025-5967

Abstract Background. Graft versus host disease (GVHD) remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem...

Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression

Zhuoer Xie, Christy James, Niraj Neupane et al. Nov 03, 2025 pp. 788-788 10.1182/blood-2025-788

Abstract Background: Chronic myelomonocytic leukemia (CMML) is a universally fatal adult myeloid neoplasm with a median survival of 32 month...

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Ivo Veletic, Taghi Manshouri, Christopher Pacheco et al. Nov 03, 2025 pp. 5542-5542 10.1182/blood-2025-5542

Abstract Background: Splenomegaly due to extramedullary hematopoiesis (EMH) is a hallmark of myelofibrosis (MF). Previous studies of splenec...

Differential expression of coagulation and inflammation genes in ITP patients before and after treatment with thrombopoietin receptor agonists

Lamya Garabet, Mark Burton, Mads Thomassen et al. Nov 03, 2025 pp. 3018-3018 10.1182/blood-2025-3018

Abstract Introduction Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet count resulting from immune-medi...

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

Luciano Costa, Albert Oriol, Dominik Dytfeld et al. Nov 03, 2025 pp. 94-94 10.1182/blood-2025-94

Abstract Introduction: The CARTITUDE-4 study (NCT04181827), which enrolled patients with lenalidomide-refractory multiple myeloma (MM) after...

Using FXIa-triggered thrombin generation to assess the risk of breakthrough bleeding in patients receiving emicizumab for acquired Hemophilia A

Fabius Pelzer, Ella Ertekin, Olga Oleshko et al. Nov 03, 2025 pp. 310-310 10.1182/blood-2025-310

Abstract The treatment of patients with acquired hemophilia A (AHA) is currently changing. Immunosuppressive therapy (IST), the standard of...

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Audrey Lasry, Bettina Nadorp, Sanam Loghavi et al. Nov 03, 2025 pp. 220-220 10.1182/blood-2025-220

Abstract Myeloid sarcoma is a distinct form of acute myeloid leukemia (AML) which affects approximately 10-15% of patients (pts) with AML. I...

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

Neng Nie, Chen Yang, Jun Shi et al. Nov 03, 2025 pp. 381-381 10.1182/blood-2025-381

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hemolytic disorder caused by somatic mutations in the PIG-...

Elevated prevalence of hereditary thrombophilia variants in an endogamous jewish-Mexican cohort

Ariela Souroujon, Sylvi Harari-Arakindji, Teresa Metta-Harari et al. Nov 03, 2025 pp. 4901-4901 10.1182/blood-2025-4901

Abstract Background: Hereditary thrombophilias (HTs) are genetic disorders associated with an increased risk of venous thromboembolism (VTE)...

CD43 functions as a CD47 independent “don't eat me” signal and novel immune checkpoint in AML

Yun Li, Chuqi Wang, Javier Sanmartín‑Martínez et al. Nov 03, 2025 pp. 5025-5025 10.1182/blood-2025-5025

Abstract CD47 has gained significant attention as a critical anti-phagocytic molecule and therapeutic target for blood cancer immunotherapy....

Heart failure readmissions in patients with iron deficiency anemia: A national readmission database analysis

Jawad Ahmed, Muhammad Umer Sohail, Asad Iqbal et al. Nov 03, 2025 pp. 6469-6469 10.1182/blood-2025-6469

Abstract Background: Heart Failure is a long-standing enervative that contributes to significant morbidity and mortality...

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

Kaiyuan Wang, Xiaoling Wang, wancheng yang et al. Nov 03, 2025 pp. 4181-4181 10.1182/blood-2025-4181

Abstract Although certain canonical mutation combination of VSVG effectively reduces the affinity between VSVG and LDLR—thereby improving tr...

Low expressed SRSF1 promotes lck exon 8 skipping to attenuate TCR signaling and treg induction in immune thrombocytopenia

Hu Xiang, Shaoqiu Leng, Jun Peng Nov 03, 2025 pp. 4779-4779 10.1182/blood-2025-4779

Abstract Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by platelet destruction and impaired production...

High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort

Joost Vermaat, Pim Mutsaers, Sébastien Anguille et al. Nov 03, 2025 pp. 5940-5940 10.1182/blood-2025-5940

Abstract Introduction:CAR T-cell therapies have revolutionized treatment for relapsed/refractory (R/R) DLBCL; however, high rates of progres...

Understanding the burden and predictors of 90-day all-cause readmissions following hospitalization for diffuse large B-cell lymphoma: An analysis of the nationwide readmissions database

Jasneet Randhawa, Bugra Zengin, Zaid Zahid et al. Nov 03, 2025 pp. 4399-4399 10.1182/blood-2025-4399

Abstract Introduction Diffuse large B-cell lymphoma accounts for one of the highest annual death rates among non-Hodgkin lymphomas, with clo...

Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Loïc Renaud, Florian Chevillon, Emilie Leveque et al. Nov 03, 2025 pp. 1019-1019 10.1182/blood-2025-1019

Abstract Background: Relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) remains a therapeutic challenge, with limited...

Survival outcomes of patients with secondary hemophagocytic lymphohistiocytosis at two academic medical centers in the United States

Catherine Broome, Daniel Hausrath, Jim Jaworski et al. Nov 03, 2025 pp. 6243-6243 10.1182/blood-2025-6243

Abstract Introduction: Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare, life-threatening hyperinflammatory syndrome characteri...

Outcomes during BTKi treatment for chronic lymphocytic leukemia: Insights from remote therapeutic monitoring

Gurjyot Doshi, Mustafa Ascha, Lee Ding et al. Nov 03, 2025 pp. 2768-2768 10.1182/blood-2025-2768

Abstract Introduction Bruton tyrosine kinase inhibitors (BTKis) are an established cornerstone therapy for chronic lymphocytic leukemia/ sma...

Genetic evolution of Waldenström macroglobulinemia across disease stages

Saurabh Zanwar, Joseph Novak, Surendra Dasari et al. Nov 03, 2025 pp. 3540-3540 10.1182/blood-2025-3540

Abstract Background: Waldenström Macroglobulinemia (WM) is an indolent B-cell lymphoplasmacytic lymphoma characterized by heterogeneous clini...

A baseline transcriptomic signature predictive of clinical response to menin inhibitors in AML : The PRE-men retrosprospective Study

Vincent Alcazer, Sandrine Hayette, Pauline Bertin-Mourot et al. Nov 03, 2025 pp. 3482-3482 10.1182/blood-2025-3482

Abstract Introduction Menin inhbitors (MENi) have been developed mainly in KMT2-r and NPM1cmut aute myeloid leukemia (AML) and showed encoura...

Hematological symptom burden and treatment patterns in patients with IgG4-related disease: A real-world, multicenter retrospective analysis

Nikhil Vojjala, Syed Fahad Gillani, Rushi Shah et al. Nov 03, 2025 pp. 4479-4479 10.1182/blood-2025-4479

Abstract Background: IgG4-related disease (IgG4-RD) is a rare, immune-mediated fibroinflammatory condition characterized by tissue infiltrat...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page